Aadi Bioscience Q2 2022: FYARRO sales $3.4M, net loss $18.3M, cash $118.7M

Whitehawk Therapeutics, Inc.

2022-Q2 EPS reported -$1.53 revenue$5,744,000

FYARRO net product sales $3.4M for Q2 2022, first full quarter after launch.
Net loss $18.3M (vs $1.5M in Q2 2021), includes $3.7M impairment charge.
Cash and equivalents $118.7M; expected to fund operations into 2024.
PRECISION 1 trial (TSC1/TSC2) enrollment ongoing; preliminary data expected 1H23.
Permanent J-code (J9331) for FYARRO effective July 1, 2022 from CMS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.